Mallinckrodt Accents Critical Care With Ikaria Acquisition
Mallinckrodt Pharmaceuticals has bought Ikaria, a privately-held critical care company, for $2.3 billion.
Mallinckrodt Pharmaceuticals, a specialty biopharmaceutical company, has inked a deal for $2.3 billion with Ikaria, a privately-held critical care company focused on the development and commercialization of innovative
therapies and delivery systems. The deal is expected to increase Mallinckrodt's net sales by $150 million.
Ikaria's leading product, FDA-approved Inomax, is a vasodilator that is designed for the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure, in conjuction with ventilatory support and
other treatments. Inomax improves oxygenation and reduces the need for extracorporeal membrane oxygenation and is specifically indicated for patients experiencing hypoxic respiratory failure associated with clinical
or endocardiographic evidence of pulmonary hypertension, according to a press release.
Source: Mallinckrodt
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.
